Volume 8, Issue 3 (10-2020)                   Jorjani Biomed J 2020, 8(3): 1-3 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

jafari S M. Role of Adenosine receptor in lung cancer. Jorjani Biomed J. 2020; 8 (3) :1-3
URL: http://goums.ac.ir/jorjanijournal/article-1-745-en.html
Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran/ Department of Biochemistry and Biophysics, School of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
Full-Text [PDF 432 kb]   (314 Downloads)     |   Abstract (HTML)  (972 Views)
Full-Text:   (179 Views)
Statement
Lung cancer is a major cause of cancer deaths worldwide with 18.4% of total cancer cases and also the most common cancer diagnosis with 11.6% of total cancer cases (1). Despite progress in cancer therapy, treatment of lung cancer has not been very successful (2). Current attempts have focused on target therapy in lung cancer with the design of drugs that block the activities of the key pathways in lung cancer (3). In recent years, adenosine signaling has emerged as a pivotal signaling pathways in different human malignant diseases (4). Because adenosine metabolism changes in lung disease, it is support critical role of adenosine in pathogenesis of lung disease (5). Adenosine initiates its cellular signaling pathways through four G protein receptors, A1, A2A, A2B and A3. The A1 and A3 adenosine receptors (AR) are coupled to Gi/o proteins and inhibit cyclic AMP production, while A2AAR and A2BAR are coupled to Gs/olf proteins and stimulate cyclic AMP production (5). High expression of adenosine receptors reported in lung cancer taking role in pathogenesis of lung cancers (6,7). It has been shown that adenosine receptors regulates survival in lung cancer cells (6,7). Inhibition of A2AAR inhibits tumor cell growth with induction of apoptosis in lung cancer (6).  It was reported adenosine and the agonist A3AR induces apoptosis in lung cancer (7). A number of study have shown crucial role adenosine receptors, especially A2BAR in lung metastasis (8-10). A2BAR regulate epithelial–mesenchymal transition in lung cancer process has been widely associated with metastasis (8). Moreover, blockade of A2BAR inhibited lung metastasis in immunodeficient mice after implantation of breast cancer cells (9). It has also been reported that inhibition of A2B AR, promote the efficacy of radiotherapy (10). Furthermore, a study indicated the expression of the A2B AR as opposite prognostic biomarker in patient with lung cancer (11). Considering the above-mentioned explanations targeting adenosine receptors have the potential regulation of survival and metastasis of lung cancer cells and can be considered as drug targets for the treatment of lung cancer.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68:394-424. [DOI:10.3322/caac.21492] [Google Scholar]
2. Worley S. Lung cancer research is taking on new challenges: knowledge of tumors' molecular diversity is opening new pathways to treatment. PT. 2014;39:698.3. [Google Scholar]
3. Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Tar. 2019;4:1-4.4. [DOI:10.1038/s41392-019-0099-9] [Google Scholar]
4. Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57. [DOI:10.1186/s40425-018-0360-8] [Google Scholar]
5. Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR. Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PloS one. 2010 .;5:e9224. [DOI:10.1371/journal.pone.0009224]
6. Mediavilla-Varela M, Luddy K, Noyes D, et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013;14:860-868. [DOI:10.4161/cbt.25643]
7. Otsuki T, Kanno T, Fujita Y, et al. A3 adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells. Cell Physiol Biochem. 2012;30:210-220. [DOI:10.1159/000339058]
8. Giacomelli C, Daniele S, Romei C, Tavanti L, Neri T, Piano I, Celi A, Martini C, Trincavelli ML. The A2B adenosine receptor modulates the epithelial-mesenchymal transition through the balance of cAMP/PKA and MAPK/ERK pathway activation in human epithelial lung cells. Front Pharmacol. 2018;9:54. [DOI:10.3389/fphar.2018.00054]
9. Lan J, Lu H, Samanta D, Salman S, Lu Y, Semenza GL. Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. Proc Natl Acad Sci U S A. 2018;115(41):E9640-8. [DOI:10.1073/pnas.1809695115]
10. Kitabatake K, Yoshida E, Kaji T, Tsukimoto M. Involvement of adenosine A2B receptor in radiation-induced translocation of epidermal growth factor receptor and DNA damage response leading to radioresistance in human lung cancer cells. BBA Gen Subjects. 2020 ;1864(1):129457. [DOI:10.1016/j.bbagen.2019.129457]
11. Inoue Y, Yoshimura K, Kurabe N, et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget. 2017;8:8738-8751. [DOI:10.18632/oncotarget.14434]
Type of Article: Letter to Editor | Subject: General medicine
Received: 2020/08/1 | Accepted: 2020/08/14 | Published: 2020/10/1

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68:394-424. [view at publisher] [DOI] [Google Scholar]
2. Worley S. Lung cancer research is taking on new challenges: knowledge of tumors' molecular diversity is opening new pathways to treatment. PT. 2014;39:698.3. [view at publisher] [Google Scholar]
3. Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Tar. 2019;4:1-4.4. [view at publisher] [DOI] [Google Scholar]
4. Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6:57. [view at publisher] [DOI] [Google Scholar]
5. Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR. Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PloS one. 2010 .;5:e9224. [view at publisher] [DOI] [Google Scholar]
6. Mediavilla-Varela M, Luddy K, Noyes D, et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol Ther. 2013;14:860-868. [view at publisher] [DOI] [Google Scholar]
7. Otsuki T, Kanno T, Fujita Y, et al. A3 adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells. Cell Physiol Biochem. 2012;30:210-220. [view at publisher] [DOI] [Google Scholar]
8. Giacomelli C, Daniele S, Romei C, Tavanti L, Neri T, Piano I, Celi A, Martini C, Trincavelli ML. The A2B adenosine receptor modulates the epithelial-mesenchymal transition through the balance of cAMP/PKA and MAPK/ERK pathway activation in human epithelial lung cells. Front Pharmacol. 2018;9:54. [view at publisher] [DOI] [Google Scholar]
9. Lan J, Lu H, Samanta D, Salman S, Lu Y, Semenza GL. Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. Proc Natl Acad Sci U S A. 2018;115(41):E9640-8. [view at publisher] [DOI] [Google Scholar]
10. Kitabatake K, Yoshida E, Kaji T, Tsukimoto M. Involvement of adenosine A2B receptor in radiation-induced translocation of epidermal growth factor receptor and DNA damage response leading to radioresistance in human lung cancer cells. BBA Gen Subjects. 2020 ;1864(1):129457. [view at publisher] [DOI] [Google Scholar]
11. Inoue Y, Yoshimura K, Kurabe N, et al. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer. Oncotarget. 2017;8:8738-8751. [view at publisher] [DOI] [Google Scholar]

Add your comments about this article : Your username or Email:
CAPTCHA

© 2021 CC BY-NC 4.0 | Jorjani Biomedicine Journal

Designed & Developed by : Yektaweb